Shucheng Liang

Dr. Shucheng Liang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
CGChaokun Guan
Chaokun Guan
LGLinjuan Guo
Linjuan Guo
SLShucheng Liang
Shucheng Liang
Background: Direct oral anticoagulants (DOACs) have been widely applied in adults for thrombosis prophylaxis. However, the effect of DOACs in pediatric patients with congenital or acquired heart diseases who need anticoagulation therapy remains unclear. Methods: We systematically searched the databases of PubMed, Embase, and the Cochrane Library, as well as the ClinicalTrials.gov registry and the World Health Organization's International Clinical Trials Registry Platform until June 2024 to identify relevant randomized clinical trials (RCTs). If the number of included studies was less than 5, we performed a narrative review to assess the effect of DOACs in pediatric patients. Results: Four studies were included. In the UNIVERSE study, thrombotic events occurred in 2% of the rivaroxaban group and 9% of the aspirin group, with bleeding events in 36% and 41%, respectively. The ENNOBLE-ATE study showed no thromboembolic events in the edoxaban group and 1.7% in the SOC group (rate difference: −0.07%, 95% CI: −0.22 to 0.07%). Major bleeding rates were similar (rate difference: −0.03%, 95% CI: −0.18 to 0.12%). The SAXOPHONE trial showed no thromboembolic events in either group and similar major bleeding rates (−0.8%, 95% CI: −8.1 to 3.3%). In the DIVERSITY trial, 81% of dabigatran patients achieved the primary outcome versus 59.3% in the SOC group (Odds ratio: 0.342, 95% CI: 0.081–1.229). No major bleeding occurred in either group. Conclusion: Existing studies suggest that the use of DOACs hold promise as an effective and safe alternative for preventing and treating thromboembolism in pediatric patients with heart conditions.

13 March 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
QNQinling Nong
Qinling Nong
SLShucheng Liang
Shucheng Liang
WZWengen Zhu
Wengen Zhu
YCYili Chen
Yili Chen
TZTang Zhang
Tang Zhang
Background: This study aimed to systematically review and synthesize evidence comparing direct oral anticoagulants (DOACs) with vitamin K antagonists (VKAs) for anticoagulation in patients with atrial fibrillation (AF) and cardiac amyloidosis (CA). Methods: A comprehensive search of PubMed and EMBASE databases was conducted through January 2024 to identify studies comparing DOACs and VKAs in AF patients with CA. Eligible studies underwent rigorous screening and data extraction to evaluate safety and efficacy outcomes. Results: Four studies met the criteria. The first study reported similar embolic event rates between DOACs (3.9%) and VKAs (2.9%) per 100 patient years, while major bleeding rates were 5.21% and 3.74%, respectively. The second paper found stroke rates of 2% for DOACs and 4% for VKAs, with bleeding complications observed in 10% of DOAC patients compared to 20% in VKA patients. The third cohort demonstrated that DOACs were associated with significantly lower risks of stroke and major bleeding compared to VKAs. The last study reported embolic event rates of 1.6 and 2.0 per 100 patient years for DOACs and VKAs, respectively. In the pooled analysis, DOACs were associated with a reduced risk of thromboembolic events (odds ratio [OR] = 0.52; 95% confidence interval [CI]: 0.32–0.84), and no difference in major bleeding between the two groups (OR = 0.61, 95% CI: 0.25–1.51). Conclusions: Existing studies support the use of DOACs as a non-inferior therapeutic option compared to VKAs for preventing thromboembolism in patients with AF and cardiac amyloidosis. DOACs may also offer practical advantages, including reduced bleeding risks and ease of management, but further high-quality randomized controlled trials are needed to confirm these findings and guide clinical practice.

1 January 2024 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
TZTang Zhang
Tang Zhang
LGLinjuan Guo
Linjuan Guo
SLShucheng Liang
Shucheng Liang
HLHao Liu
Hao Liu
Direct oral anticoagulants (DOACs) are becoming increasingly popular clinically, but their safety and effectiveness profile in patients with chronic thromboembolic pulmonary hypertension (CTEPH) is not well-established. Literature from the PubMed and EMBASE databases was systematically screened up to February 2024 to identify relevant studies on the use of DOACs in CTEPH patients. The bias risk of RCTs was assessed using the Cochrane Risk of Bias Tool 2.0. The quality of observational prospective cohorts was assessed using the Newcastle-Ottawa Scale tool. Data pooled from different studies were analyzed. Results from 4 studies were gathered, including 2 randomized controlled trials and 2 prospective cohorts, with a total of 2038 patients, of which 751 were on DOACs and 1287 were on vitamin K antagonists (VKAs). Similar rates of all-cause mortality (3.33% vs 3.33%, RD = −0.01%, 95% CI [−0.02%, 0.00%], P = .17), VTE recurrence (1.46% vs 2.12%, RD = −0.00%, 95% CI [−0.01%, 0.01%], P = .92) were observed. DOACs were associated with a nonsignificant reduction in bleeding events including major bleeding (2.22% vs 3.71%, RD = −0.01%, 95% CI [−0.04%, 0.01%], P = .30), any bleeding (5.33% vs 9.94%, RD = −0.03%, 95% CI [−0.07%, 0.01%], P = .10), and minor bleeding (4.17% vs 13.3%, RD = −0.06%, 95% CI [−0.23%, 0.10%], P = .45). Data pooled from existing perspective trials suggests the use of DOACs in CTEPH patients as an effective and safe alternative to VKAs.

16 November 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
GGGuigao Guo
Guigao Guo
SLShucheng Liang
Shucheng Liang
ZGZeyu Guan
Zeyu Guan
KZKe Zhu
Ke Zhu
Background: Several studies have summarized the clinical performance of direct oral anticoagulants (DOACs) in atrial fibrillation (AF) patients with mitral stenosis or aortic stenosis. The significance of this review was to provide clinicians the latest update of the clinical application of DOACs in managing this specific population.Methods: Literatures from the PubMed database up to July 2022 were screened for inclusion. Studies on the effect of DOACs in patients suffering from AF with mitral or aortic stenosis were assessed for further selection.Results: Results from four studies were gathered: the RISE MS trial, the DAVID-MS study, and two observational studies. In the Korean observational study with a 27-month follow-up duration and a sample population consisted of patients with mitral stenosis and AF, the thromboembolic events happened at a rate of 2.22%/ year in the DOAC group and 4.19%/year in the warfarin group (adjusted hazard ratio: 0.28; 95% CI: 0.18–0.45). Intracranial hemorrhage occurred at rates of 0.49% and 0.93% in the DOAC and the warfarin groups, respectively (adjusted hazard ratio: 0.53; 95% CI: 0.22–1.26). In the Danish observational study, which had a sample pool with AF patients with aortic stenosis, reported that the adjusted hazard ratios for thromboembolism and major bleeding were 1.62 (95% CI, 1.08–2.45) and 0.73 (95% CI, 0.59–0.91) for DOACs compared with warfarin during 3 years of follow-up. In the RISE-MS trial involving AF patients with mitral stenosis, there were no differences in ischemic stroke, systemic embolic events, or major bleeding between the rivaroxaban vs. warfarin groups during a 1-year follow-up as well as equal rate of increased thrombogenicity in the left atrial appendage at 6 months. The rate of silent cerebral ischemia at 12 months was higher in the warfarin group (17.6%) than that in the rivaroxaban group (13.3%).Conclusions: Current published studies supported DOACs' effectiveness in preventing thromboembolism in patients of AF with mitral or aortic stenosis. Further clinical trials could confirm these findings.

1 January 2026 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
SLShucheng Liang
Shucheng Liang
XCXi Chen
Xi Chen
DWDanghan Wang
Danghan Wang
WZWengen Zhu
Wengen Zhu
KQKai Qiu
Kai Qiu
Background: This study aimed to systematically review randomized controlled trials (RCTs) comparing oral anticoagulant (OAC) monotherapy with combination therapy of OAC plus single antiplatelet therapy (SAPT) in patients with chronic coronary syndrome (CCS) and an indication for long-term anticoagulation. Methods: A systematic screening of the PubMed, EMBASE and Cochrane Central databases was conducted until 12 Mar 2026 to identify RCTs comparing OAC monotherapy with OAC plus SAPT in CCS patients. The primary endpoints were all-cause mortality and net adverse clinical events (NACE). Secondary endpoints included major bleeding, cardiovascular death, myocardial infarction, ischemic stroke and stroke. End point data were pooled using random-effect models, to generate hazard ratios (HR) and odds ratios (OR) and corresponding 95% confidence intervals (CI). Results: Six RCTs involving 5048 patients were included. Pooled analysis showed that OAC monotherapy significantly reduced the risk of NACE compared to combination therapy (HR, 0.66; 95% CI, 0.44–0.77). There was no significant difference in all-cause mortality overall (HR, 0.75; 95% CI, 0.51–1.10). OAC monotherapy substantially decreased major bleeding (HR, 0.47; 95% CI, 0.32–0.70) and cardiovascular death (HR, 0.69; 95% CI 0.50–0.95) and there was no statistically significant difference in other secondary outcomes. Conclusions: Current evidence suggests that OAC monotherapy is a safer alternative to combination therapy in anticoagulated patients with CCS, without increasing ischemic risk.